AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18377647 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurythmy therapy (EYT) as an add-on treatment
Number of subjects: 898
Study 18377647 — intervention group
Group type: COMPARATOR
Intervention: Eurythmy therapy (EYT)
Number of subjects: 898
Study 16153010 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline ethanoate of piperazine suppositories (Minophylline 500 mg)
Number of subjects: 24
Study 16153010 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) theophylline ethanoate of piperazine (Minophylline ampoules 500 mg)
Number of subjects: 24
Study 12502668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg/day
Number of subjects: 195
Study 12502668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 20 mg/day
Number of subjects: 195
Study 12502668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 12502668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (both doses)
Number of subjects: 195
Study 10228287 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene wrap applied immediately at birth
Number of subjects: 62
Study 10228287 — intervention group
Group type: COMPARATOR
Intervention: Non-wrap group (control)
Number of subjects: 62
Study 8911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous ex vivo activated T‐lymphocytes and cimetidine (ALT)
Number of subjects: 90
Study 8911510 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 90
Study 8911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with ALT
Number of subjects: 90
Study 8911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated alkaline phosphatase (AP) levels
Number of subjects: 90
Study 8911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal alkaline phosphatase (AP) levels
Number of subjects: 90
Study 8911510 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bone metastases
Number of subjects: 90
Study 1801563 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge scripts (imagery scripts with explicit descriptions of smoking urge situations)
Number of subjects: 66
Study 1801563 — intervention group
Group type: COMPARATOR
Intervention: Neutral scripts (imagery scripts devoid of explicit urge content)
Number of subjects: 66
Study 1801563 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge scripts
Number of subjects: 66
Study 1801563 — intervention group
Group type: COMPARATOR
Intervention: Neutral scripts
Number of subjects: 66
Study 6847217 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral UV-B phototherapy
Number of subjects: 20
Study 6847217 — intervention group
Group type: COMPARATOR
Intervention: Untreated side
Number of subjects: 20
Study 31740017 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Cigarettes (EC) with nicotine
Number of subjects: 0
Study 31740017 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Cigarettes (EC) without nicotine
Number of subjects: 0
Study 31740017 — intervention group
Group type: COMPARATOR
Intervention: Tobacco Cigarettes (TC)
Number of subjects: 0
Study 29426261 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue dye‐guided lymph channel ligation
Number of subjects: 0
Study 29426261 — intervention group
Group type: COMPARATOR
Intervention: Control (standard inguinal lymphadenectomy without blue dye guidance)
Number of subjects: 0
Study 26993261 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of renal replacement therapy
Number of subjects: 0
Study 26993261 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of renal replacement therapy
Number of subjects: 0
Study 24332419 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer-generation drug-eluting stents (everolimus-eluting stent or biolimus A9-eluting stent)
Number of subjects: 2665
Study 24332419 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2665
Study 22513012 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Health Program (OHP), a nine-session self-management intervention
Number of subjects: 0
Study 22513012 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus Optimal Health Program (OHP)
Number of subjects: 0
Study 22513012 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 0
Study 20375277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anticoagulant 2-O,3-O-desulfated heparin (ODSH)
Number of subjects: 0
Study 20375277 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 17493184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided from admission to discharge by a specialist clinical pharmacist
Number of subjects: 203
Study 17493184 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 203
Study 17315407 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid opioid detoxification (ROD)
Number of subjects: 80
Study 17315407 — intervention group
Group type: COMPARATOR
Intervention: Clonidine-assisted detoxification (CD)
Number of subjects: 80
Study 11486702 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide 600 mg/m2 plus carboplatin 300 mg/m2 (conventional dose)
Number of subjects: 91
Study 11486702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 plus carboplatin 600 mg/m2 (intensive dose)
Number of subjects: 91
Study 9917680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluted 10-mm diameter femoral intramedullary alignment rod
Number of subjects: 48
Study 9917680 — intervention group
Group type: COMPARATOR
Intervention: Round 10-mm diameter femoral intramedullary alignment rod
Number of subjects: 48
Study 7798466 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 48
Study 7798466 — intervention group
Group type: COMPARATOR
Intervention: Imipramine (IMI)
Number of subjects: 48
Study 3053320 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute alcohol
Number of subjects: 11
Study 3053320 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol
Number of subjects: 11
Study 1110274 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxed wakefulness condition (subjects instructed to relax but stay awake)
Number of subjects: 20
Study 31465092 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10^11 genome particles)
Number of subjects: 6
Study 31465092 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (untreated)
Number of subjects: 6
Study 31465092 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy
Number of subjects: 6
Study 27694534 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater income
Number of subjects: 202
Study 27694534 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater pain interference
Number of subjects: 202
Study 27694534 — intervention group
Group type: EXPERIMENTAL
Intervention: Less pain interference with lower levels of depressive symptoms
Number of subjects: 202
Study 26969273 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole prophylaxis (TSP)
Number of subjects: 571
Study 26969273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571
Study 24954781 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1062
Study 24954781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemoimmunotherapy (chemotherapy with sequential GV1001)
Number of subjects: 1062
Study 24954781 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoimmunotherapy (chemotherapy with concurrent GV1001)
Number of subjects: 1062
Study 22224877 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-focused interventions (e.g., school-based programs, community coalitions)
Number of subjects: 0
Study 22224877 — intervention group
Group type: EXPERIMENTAL
Intervention: Programs using electronic media and phone links
Number of subjects: 0
Study 22224877 — intervention group
Group type: EXPERIMENTAL
Intervention: Policy and systems changes through community coalitions
Number of subjects: 0
Study 22224877 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparisons among proven asthma control interventions
Number of subjects: 0
Study 19008007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) therapy
Number of subjects: 54
Study 19008007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone plus insulin (INS+RSG)
Number of subjects: 54
Study 19008007 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone (INS)
Number of subjects: 54
Study 19008007 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas (SUs)
Number of subjects: 54
Study 18219838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 144
Study 18219838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 800 microg
Number of subjects: 144
Study 18219838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 18219838 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol
Number of subjects: 144
Study 15500597 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (58 mg subcutaneous depot injection)
Number of subjects: 15
Study 15500597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11771571 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexibuprofen 400 mg t.i.d.
Number of subjects: 401
Study 11771571 — intervention group
Group type: COMPARATOR
Intervention: Dexibuprofen
Number of subjects: 401
Study 11771571 — intervention group
Group type: COMPARATOR
Intervention: Racemic ibuprofen 800 mg t.i.d.
Number of subjects: 401
Study 11771571 — intervention group
Group type: COMPARATOR
Intervention: Racemic ibuprofen 2400 mg daily
Number of subjects: 401
Study 9296411 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 381
Study 9296411 — intervention group
Group type: COMPARATOR
Intervention: Tracheal Tube (TT)
Number of subjects: 381
Study 8329290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 16
Study 8329290 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 16
Study 3731904 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilatory muscle exercise training (VMT) using a prototype, portable device for isocapnic hyperventilation training.
Number of subjects: 18
Study 3731904 — intervention group
Group type: COMPARATOR
Intervention: Walking exercise training.
Number of subjects: 18
Study 29520799 — intervention group
Group type: COMPARATOR
Intervention: Source plasma donation frequency (70 or more donations)
Number of subjects: 1254
Study 29520799 — intervention group
Group type: COMPARATOR
Intervention: Source plasma donation frequency (1 to 24 donations)
Number of subjects: 1254
Study 29520799 — intervention group
Group type: COMPARATOR
Intervention: Source plasma donation frequency (highest-frequency donors)
Number of subjects: 1254
Study 29520799 — intervention group
Group type: COMPARATOR
Intervention: New donors (control group)
Number of subjects: 1254
Study 29520799 — intervention group
Group type: COMPARATOR
Intervention: Highest-frequency donors (control group)
Number of subjects: 1254
Study 27258806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 56
Study 27258806 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 56
Study 27258806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (aerobic + resistance)
Number of subjects: 56
Study 27258806 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 24609465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued approach training (auditory cue with simple motor response)
Number of subjects: 0
Study 22611313 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (32 g/d for 12 weeks)
Number of subjects: 160
Study 22611313 — intervention group
Group type: COMPARATOR
Intervention: Casein supplementation (control group, 32 g/d for 12 weeks)
Number of subjects: 160
Study 20923082 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor recognition when participants judged the odor to fit the imagined episode
Number of subjects: 32
Study 20923082 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor recognition with unpleasant odor incongruously paired with a warm episode
Number of subjects: 32
Study 20923082 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor recognition when narrative outlines described familiar characters
Number of subjects: 32
Study 19022964 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40-45 en% fat)
Number of subjects: 613
Study 19022964 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20-25 en% fat)
Number of subjects: 613
Study 19022964 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss program
Number of subjects: 613
Study 19022964 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial RLP-C
Number of subjects: 613
Study 19022964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting RLP-C
Number of subjects: 613
Study 16910917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss (3 months)
Number of subjects: 20
Study 16910917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-Oss (6 months)
Number of subjects: 20
Study 16910917 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-existing subantral bone)
Number of subjects: 20
Study 16910917 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between group A (3 months) and group B (6 months)
Number of subjects: 20
Study 16910917 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF expression (group A vs group B)
Number of subjects: 20
Study 15030306 — intervention group
Group type: EXPERIMENTAL
Intervention: Shigella infection
Number of subjects: 0
Study 15030306 — intervention group
Group type: EXPERIMENTAL
Intervention: Proinflammatory mediators production
Number of subjects: 0
Study 15030306 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive immune response
Number of subjects: 0
Study 11114678 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) dietary intake from D0 to D15
Number of subjects: 45
Study 11114678 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) dietary intake from D0 to W37
Number of subjects: 45
Study 11114678 — intervention group
Group type: EXPERIMENTAL
Intervention: Linolenic acid (LA) dietary intake from D0 to D15
Number of subjects: 45
Study 11114678 — intervention group
Group type: EXPERIMENTAL
Intervention: Linolenic acid (LA) dietary intake from D0 to W37
Number of subjects: 45
Study 8857632 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (NTG) 5-mg patch per day over 3 days
Number of subjects: 20
Study 8857632 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 20
Study 8501145 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 11
Study 8501145 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glucose meal
Number of subjects: 11
Study 8501145 — intervention group
Group type: COMPARATOR
Intervention: Placebo meal
Number of subjects: 11
Study 3330182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual prazepam
Number of subjects: 5
Study 3330182 — intervention group
Group type: COMPARATOR
Intervention: Oral prazepam
Number of subjects: 5
Study 28499696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200mg/day)
Number of subjects: 102
Study 27716293 — intervention group
Group type: COMPARATOR
Intervention: TNT009, a humanized monoclonal antibody directed against the C1s subunit of human complement component C1, administered in a double-blind, randomized, placebo-controlled manner.
Number of subjects: 1
Study 24302706 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional Health Assessment Questionnaire (MDHAQ)
Number of subjects: 980
Study 24302706 — intervention group
Group type: EXPERIMENTAL
Intervention: Multinomial logistic regression
Number of subjects: 980
Study 22882646 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MTZ) 400 mg/TID and Amoxicillin (AMX) 500 mg/TID for 14 days
Number of subjects: 30
Study 22882646 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 30
Study 20073214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal massage for 20 min once every other day
Number of subjects: 60
Study 20073214 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy with Premarin 0.625 g, once daily by oral taking
Number of subjects: 60
Study 20073214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicinal massage
Number of subjects: 60
Study 20073214 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy
Number of subjects: 60
Study 18085903 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention induction embedded in the questionnaire
Number of subjects: 390
Study 18085903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implementation intention induction)
Number of subjects: 390
Study 18085903 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention induction among participants who returned the questionnaire
Number of subjects: 390
Study 18085903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implementation intention induction) among participants who returned the questionnaire
Number of subjects: 390
Study 15636449 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 116
Study 15636449 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 116
Study 12171079 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9020242 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet supplemented with monounsaturated fat
Number of subjects: 24
Study 9020242 — intervention group
Group type: COMPARATOR
Intervention: Very-low-fat diet
Number of subjects: 24
Study 8182900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) administered intravenously at a dosage of 3 mg/kg
Number of subjects: 4
Study 8182900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) administered orally
Number of subjects: 4
Study 8182900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLCZ) administered intravenously
Number of subjects: 4
Study 3235820 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at several doses
Number of subjects: 20
Study 3235820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30081730 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabin cervical pessary and progesterone
Number of subjects: 217
Study 29291549 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-delivered brief intervention with booster
Number of subjects: 780
Study 29291549 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC-ED)
Number of subjects: 780
Study 26558293 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell therapy (mesenchymal stem cells and neural fetal stem cells)
Number of subjects: 0
Study 26558293 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24716671 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan procedure patients
Number of subjects: 25
Study 24716671 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 25
Study 23725917 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (600 mg daily)
Number of subjects: 0
Study 23725917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20642205 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% bepotastine besilate ophthalmic solution
Number of subjects: 71
Study 20642205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 18377661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis-only
Number of subjects: 72
Study 18377661 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus quadrangularis/Irvingia gabonensis combination
Number of subjects: 72
Study 18377661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 16360618 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced variety condition (limited snack food intake to one chosen snack food)
Number of subjects: 30
Study 16360618 — intervention group
Group type: COMPARATOR
Intervention: Control condition (limited snack food intake to <1 serving/day with no variety limit)
Number of subjects: 30
Study 14696884 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg)
Number of subjects: 44
Study 14696884 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg)
Number of subjects: 44
Study 14696884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regimen of acetazolamide and dexamethasone
Number of subjects: 44
Study 14696884 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamin)
Number of subjects: 44
Study 14696884 — intervention group
Group type: EXPERIMENTAL
Intervention: Acclimatised group (20 subjects)
Number of subjects: 44
Study 10999797 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg109 homozygotes
Number of subjects: 284
Study 10999797 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg223 homozygotes
Number of subjects: 284
Study 10999797 — intervention group
Group type: COMPARATOR
Intervention: Lys109 homozygotes
Number of subjects: 284
Study 10999797 — intervention group
Group type: COMPARATOR
Intervention: Men with blood pressure >= 140/90 mm Hg
Number of subjects: 284
Study 8788355 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group (four 40-min sessions)
Number of subjects: 123
Study 8788355 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention group (four 40-min sessions by a psychologist)
Number of subjects: 123
Study 8788355 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre- and post-testing only)
Number of subjects: 123
Study 8788355 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 123
Study 8788355 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention group
Number of subjects: 123
Study 8788355 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group
Number of subjects: 123